Share on LinkedInShare on LinkedIn

ARTICLE · 29 JANUARY 2020

Phase 1 U.S. China Trade Deal: Patent Provisions

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

President Trump and China vice-premier Liu He signed a preliminary Economic and Trade Agreement ("the Agreement") on January 15, 2020. In the press, it is referred to as "Phase 1."

GlobalIntellectual Property

President Trump and China vice-premier Liu He signed a preliminary Economic and Trade Agreement ("the Agreement") on January 15, 2020. In the press, it is referred to as "Phase 1." Chapter 1 of the Agreement includes provisions related to intellectual property, and among those provisions are some patent related provisions that should be welcomed by innovative pharmaceutical patent holders. According to Art. 8.3, the Agreement shall enter into force within 30 days of signature by both Parties or the date on which the Parties notify each other in writing of the completion of their respective applicable domestic procedures, whichever is sooner. It is probably safe to say that the 30-day deadline will come sooner, so the Agreement should enter into force on Feb. 14, 2020.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from